646 related articles for article (PubMed ID: 33786600)
1. Vedolizumab and Anti-Tumour Necrosis Factor α Real-World Outcomes in Biologic-Naïve Inflammatory Bowel Disease Patients: Results from the EVOLVE Study.
Bressler B; Yarur A; Silverberg MS; Bassel M; Bellaguarda E; Fourment C; Gatopoulou A; Karatzas P; Kopylov U; Michalopoulos G; Michopoulos S; Navaneethan U; Rubin DT; Siffledeen J; Singh A; Soufleris K; Stein D; Demuth D; Mantzaris GJ
J Crohns Colitis; 2021 Oct; 15(10):1694-1706. PubMed ID: 33786600
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness and safety of vedolizumab and infliximab in biologic-naive patients with Crohn's disease: results from the EVOLVE study.
Mantzaris GJ; Bressler B; Adsul S; Luo M; Colby C; Brett NR; Saha S; Kamble P; Wang S; Yarur A
Eur J Gastroenterol Hepatol; 2024 Mar; 36(3):281-291. PubMed ID: 38179874
[TBL] [Abstract][Full Text] [Related]
3. Real-world clinical effectiveness and safety of vedolizumab and anti-tumor necrosis factor alpha treatment in ulcerative colitis and Crohn's disease patients: a German retrospective chart review.
Helwig U; Mross M; Schubert S; Hartmann H; Brandes A; Stein D; Kempf C; Knop J; Campbell-Hill S; Ehehalt R
BMC Gastroenterol; 2020 Jul; 20(1):211. PubMed ID: 32640990
[TBL] [Abstract][Full Text] [Related]
4. Systematic review with meta-analysis: real-world effectiveness and safety of vedolizumab in patients with inflammatory bowel disease.
Schreiber S; Dignass A; Peyrin-Biroulet L; Hather G; Demuth D; Mosli M; Curtis R; Khalid JM; Loftus EV
J Gastroenterol; 2018 Sep; 53(9):1048-1064. PubMed ID: 29869016
[TBL] [Abstract][Full Text] [Related]
5. Safety and effectiveness of vedolizumab in paediatric patients with inflammatory bowel disease: an observational multicentre Spanish study.
Garcia-Romero R; Martinez de Zabarte Fernandez JM; Pujol-Muncunill G; Donat-Aliaga E; Segarra-Cantón O; Irastorza-Terradillos I; Medina-Benitez E; Ruiz-Hernández CJ; Carrillo-Palau M; Ros-Arnal I; Rodriguez-Martínez A; Escartin-Madurga L; Gutiérrez-Junquera C; Vicente-Santamaría S; Velasco Rodriguez-Belvis M; Fernández-Fernández S; Alberto-Alonso JR; Montraveta M; Torres-Peral R; Navalon-Rubio M; Navas-López VM; Martin de Carpi J
Eur J Pediatr; 2021 Sep; 180(9):3029-3038. PubMed ID: 33880650
[TBL] [Abstract][Full Text] [Related]
6. Real-world Effectiveness and Safety of Vedolizumab for the Treatment of Inflammatory Bowel Disease: The Scottish Vedolizumab Cohort.
Plevris N; Chuah CS; Allen RM; Arnott ID; Brennan PN; Chaudhary S; Churchhouse AMD; Din S; Donoghue E; Gaya DR; Groome M; Jafferbhoy HM; Jenkinson PW; Lam WL; Lyons M; Macdonald JC; MacMaster M; Mowat C; Naismith GD; Potts LF; Saffouri E; Seenan JP; Sengupta A; Shasi P; Sutherland DI; Todd JA; Veryan J; Watson AJM; Watts DA; Jones GR; Lees CW
J Crohns Colitis; 2019 Sep; 13(9):1111-1120. PubMed ID: 30768123
[TBL] [Abstract][Full Text] [Related]
7. Factors influencing the outcome of vedolizumab treatment: Real-life data with objective outcome measurements.
Mader O; Juillerat P; Biedermann L; Michetti P; Hruz P; Pittet V; Rogler G; Zahnd-Straumann N; Seibold F
United European Gastroenterol J; 2021 Apr; 9(3):398-406. PubMed ID: 33203339
[TBL] [Abstract][Full Text] [Related]
8. Stratified Patient Profiling for Vedolizumab Effectiveness in Crohn's Disease: Identifying Optimal Subgroups for Enhanced Treatment Response in the EVOLVE Study.
Yarur A; Mantzaris GJ; Wang S; Adsul S; Kamble P; Cook E; Sajeev G; Guerin A; Bressler B
Adv Ther; 2024 Jun; 41(6):2324-2341. PubMed ID: 38658485
[TBL] [Abstract][Full Text] [Related]
9. Vedolizumab for Ulcerative Colitis: Treatment Outcomes from the VICTORY Consortium.
Narula N; Peerani F; Meserve J; Kochhar G; Chaudrey K; Hartke J; Chilukuri P; Koliani-Pace J; Winters A; Katta L; Shmidt E; Hirten R; Faleck D; Parikh MP; Whitehead D; Boland BS; Singh S; Sagi SV; Fischer M; Chang S; Barocas M; Luo M; Lasch K; Bohm M; Lukin D; Sultan K; Swaminath A; Hudesman D; Gupta N; Shen B; Kane S; Loftus EV; Siegel CA; Sands BE; Colombel JF; Sandborn WJ; Dulai PS
Am J Gastroenterol; 2018 Sep; 113(9):1345. PubMed ID: 29946178
[TBL] [Abstract][Full Text] [Related]
10. Multi-Center Experience of Vedolizumab Effectiveness in Pediatric Inflammatory Bowel Disease.
Singh N; Rabizadeh S; Jossen J; Pittman N; Check M; Hashemi G; Phan BL; Hyams JS; Dubinsky MC
Inflamm Bowel Dis; 2016 Sep; 22(9):2121-6. PubMed ID: 27542130
[TBL] [Abstract][Full Text] [Related]
11. Biologic Therapy for Inflammatory Bowel Disease: Real-World Comparative Effectiveness and Impact of Drug Sequencing in 13 222 Patients within the UK IBD BioResource.
Kapizioni C; Desoki R; Lam D; Balendran K; Al-Sulais E; Subramanian S; Rimmer JE; De La Revilla Negro J; Pavey H; Pele L; Brooks J; Moran GW; Irving PM; Limdi JK; Lamb CA; ; Parkes M; Raine T
J Crohns Colitis; 2024 Jun; 18(6):790-800. PubMed ID: 38041850
[TBL] [Abstract][Full Text] [Related]
12. Vedolizumab as first-line biological therapy in elderly patients and those with contraindications for anti-TNF therapy: a real-world, nationwide cohort of patients with inflammatory bowel diseases.
Attauabi M; Höglund C; Fassov J; Pedersen KB; Hansen HB; Wildt S; Jensen MD; Neumann A; Lind C; Jacobsen HA; Popa AM; Kjeldsen J; Pedersen N; Molazahi A; Haderslev K; Aalykke C; Knudsen T; Cebula W; Munkholm P; Bendtsen F; Seidelin JB; Burisch J
Scand J Gastroenterol; 2021 Sep; 56(9):1040-1048. PubMed ID: 34224299
[TBL] [Abstract][Full Text] [Related]
13. High treatment persistence rate and significant endoscopic healing among real-life patients treated with vedolizumab - a Finnish Nationwide Inflammatory Bowel Disease Cohort Study (FINVEDO)
Ylisaukko-Oja T; Aaltonen J; Nuutinen H; Blomster T; Jussila A; Pajala M; Salminen K; Moilanen V; Hakala K; Kellokumpu M; Toljamo K; Rautiainen H; Kuisma J; Peräaho M; Molander P; Silvennoinen J; Liukkonen V; Henricson H; Tillonen J; Esterinen M; Nielsen C; Hirsi E; Lääne M; Suhonen UM; Vihriälä I; Mäkelä P; Puhto M; Punkkinen J; Sulonen H; Herrala S; Jokelainen J; Tamminen K; Sipponen T
Scand J Gastroenterol; 2018 Feb; 53(2):158-167. PubMed ID: 29258369
[TBL] [Abstract][Full Text] [Related]
14. Shorter Disease Duration Is Associated With Higher Rates of Response to Vedolizumab in Patients With Crohn's Disease But Not Ulcerative Colitis.
Faleck DM; Winters A; Chablaney S; Shashi P; Meserve J; Weiss A; Aniwan S; Koliani-Pace JL; Kochhar G; Boland BS; Singh S; Hirten R; Shmidt E; Kesar V; Lasch K; Luo M; Bohm M; Varma S; Fischer M; Hudesman D; Chang S; Lukin D; Sultan K; Swaminath A; Gupta N; Siegel CA; Shen B; Sandborn WJ; Kane S; Loftus EV; Sands BE; Colombel JF; Dulai PS; Ungaro R
Clin Gastroenterol Hepatol; 2019 Nov; 17(12):2497-2505.e1. PubMed ID: 30625408
[TBL] [Abstract][Full Text] [Related]
15. Long-term efficacy and safety of vedolizumab in patients with inflammatory bowel diseases: A real-life experience from a tertiary referral center.
Dragoni G; Bagnoli S; Le Grazie M; Campani C; Rogai F; Manetti N; Bensi C; Macrì G; Galli A; Milla M
J Dig Dis; 2019 May; 20(5):235-242. PubMed ID: 30927309
[TBL] [Abstract][Full Text] [Related]
16. Changes in Vedolizumab Utilization Across US Academic Centers and Community Practice Are Associated With Improved Effectiveness and Disease Outcomes.
Koliani-Pace JL; Singh S; Luo M; Hirten R; Aniwan S; Kochhar G; Chang S; Lukin D; Gao Y; Bohm M; Swaminath A; Gupta N; Shmidt E; Meserve J; Winters A; Chablaney S; Faleck DM; Yang J; Huang Z; Boland BS; Shashi P; Weiss A; Hudesman D; Varma S; Fischer M; Sultan K; Shen B; Kane S; Loftus EV; Sands BE; Colombel JF; Sandborn WJ; Lasch K; Siegel CA; Dulai PS
Inflamm Bowel Dis; 2019 Oct; 25(11):1854-1861. PubMed ID: 31050734
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness and persistence of Vedolizumab in patients with inflammatory bowel disease : results from the Belgian REal-LIfe study with VEdolizumab (Be-RELIVE).
Reenaers C; Cremer A; Dewit O; De Vroey B; Van Moerkercke W; Bossuyt P; Muls V; Imschoot J; Block S; Hantson A; Van Hootegem P
Acta Gastroenterol Belg; 2020; 83(1):15-23. PubMed ID: 32233267
[TBL] [Abstract][Full Text] [Related]
18. Exposure-efficacy Relationships for Vedolizumab Induction Therapy in Patients with Ulcerative Colitis or Crohn's Disease.
Rosario M; French JL; Dirks NL; Sankoh S; Parikh A; Yang H; Danese S; Colombel JF; Smyth M; Sandborn WJ; Feagan BG; Reinisch W; Sands BE; Sans M; Fox I
J Crohns Colitis; 2017 Aug; 11(8):921-929. PubMed ID: 28333288
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness and Safety of Vedolizumab in Anti-TNF-Naïve Patients With Inflammatory Bowel Disease-A Multicenter Retrospective European Study.
Kopylov U; Verstockt B; Biedermann L; Sebastian S; Pugliese D; Sonnenberg E; Steinhagen P; Arebi N; Ron Y; Kucharzik T; Roblin X; Ungar B; Shitrit AB; Ardizzone S; Molander P; Coletta M; Peyrin-Biroulet L; Bossuyt P; Avni-Biron I; Tsoukali E; Allocca M; Katsanos K; Raine T; Sipponen T; Fiorino G; Ben-Horin S; Eliakim R; Armuzzi A; Siegmund B; Baumgart DC; Kamperidis N; Maharshak N; Maaser C; Mantzaris G; Yanai H; Christodoulou DK; Dotan I; Ferrante M
Inflamm Bowel Dis; 2018 Oct; 24(11):2442-2451. PubMed ID: 29788318
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness and Safety of Vedolizumab Induction Therapy for Patients With Inflammatory Bowel Disease.
Amiot A; Grimaud JC; Peyrin-Biroulet L; Filippi J; Pariente B; Roblin X; Buisson A; Stefanescu C; Trang-Poisson C; Altwegg R; Marteau P; Vaysse T; Bourrier A; Nancey S; Laharie D; Allez M; Savoye G; Moreau J; Gagniere C; Vuitton L; Viennot S; Aubourg A; Pelletier AL; Bouguen G; Abitbol V; Bouhnik Y; ;
Clin Gastroenterol Hepatol; 2016 Nov; 14(11):1593-1601.e2. PubMed ID: 26917043
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]